Company
Headquarters: Xiamen, China
Employees: 984
CN¥28.67 Billion
CNY as of Jan. 1, 2025
US$3.93 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Xiamen Amoytop Biotech Co., Ltd. engages in the manufacture, marketing, and sale of recombinant protein drugs using genetic engineering technology in China. It offers formulations, reagents, and APIs, as well as custom-manufacturing services. The company was founded in 1996 and is based in Xiamen, China.
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥2.60 B |
| EBITDA | CN¥850.0 M |
| Gross Profit TTM | CN¥1.96 B |
| Profit Margin | 28.54% |
| Operating Margin | 38.65% |
| Quarterly Revenue Growth | 37.50% |
Xiamen Amoytop Biotech Co. Ltd has the following listings and related stock indices.
Stock: SSE: 688278 wb_incandescent